The increasing cost of biological products for oncology supportive care highlights the importance of fostering competition and choice in the market. UDENYCA has been approved by the FDA as a biosimilar to Neulasta, offering similar benefits in terms of indication, dose, strength, formulation, and route of administration. This review discusses the advantages of UDENYCA, including its cost-effectiveness, and provides expert recommendations on how to successfully integrate biosimilars like UDENYCA into a healthcare system. Ultimately, the availability of biosimilars like UDENYCA can help address the rising costs of oncology supportive care.
Source link
UDENYCA® (pegfilgrastim-cbqv)
